Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Phibro Animal Health (PAHC) Shares Outstanding (Weighted Average) (2016 - 2022)

Historic Shares Outstanding (Weighted Average) for Phibro Animal Health (PAHC) over the last 10 years, with Q1 2022 value amounting to $40.5 million.

  • Phibro Animal Health's Shares Outstanding (Weighted Average) rose 5.19% to $40.5 million in Q1 2022 from the same period last year, while for Mar 2022 it was $40.5 million, marking a year-over-year increase of 5.19%. This contributed to the annual value of $40412.0 for FY2019, which is 57.49% up from last year.
  • According to the latest figures from Q1 2022, Phibro Animal Health's Shares Outstanding (Weighted Average) is $40.5 million, which was up 5.19% from $40.5 million recorded in Q4 2021.
  • In the past 5 years, Phibro Animal Health's Shares Outstanding (Weighted Average) registered a high of $40.5 million during Q3 2021, and its lowest value of $40181.0 during Q2 2018.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $32.4 million, with a median of $40.5 million in 2019.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first soared by 10096398.96% in 2018, then changed by 0.0% in 2020.
  • Phibro Animal Health's Shares Outstanding (Weighted Average) (Quarter) stood at $40.4 million in 2018, then increased by 0.18% to $40.5 million in 2019, then changed by 0.0% to $40.5 million in 2020, then grew by 0.12% to $40.5 million in 2021, then changed by 0.0% to $40.5 million in 2022.
  • Its Shares Outstanding (Weighted Average) stands at $40.5 million for Q1 2022, versus $40.5 million for Q4 2021 and $40.5 million for Q3 2021.